Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
18 hedge funds and large institutions have $41.3K invested in Iterum Therapeutics in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 8 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.51% less ownership
Funds ownership: 3.16% → 2.65% (-0.51%)
10% less funds holding
Funds holding: 20 → 18 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
93% less capital invested
Capital invested by funds: $558K → $41.3K (-$517K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$223K |
| 2 |
JF
Jump Financial
Chicago,
Illinois
|
+$18.1K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$12.4K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$8.78K |
| 5 |
KF
Krilogy Financial
St. Louis,
Missouri
|
+$7.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AF
Apollon Financial
Mount Pleasant,
South Carolina
|
-$211K |
| 2 |
Jane Street
New York
|
-$97K |
| 3 |
AW
Alchemi Wealth
Essex,
Connecticut
|
-$90.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$29.3K |
| 5 |
VF
Virtu Financial
New York
|
-$7K |
ITRM Hedge Fund Activity: Q1 2026 in Review
18 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Iterum Therapeutics (ITRM) for Q1 2026, worth a combined $41.3K — down 93% from $558K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ITRM and 6 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $223K. The largest seller was Apollon Financial, exiting entirely with an estimated $211K sold.
- 18 institutional investors held Iterum Therapeutics (ITRM) as of Q1 2026, down from 20 in Q4 2025.
- Funds reported $41.3K of Iterum Therapeutics stock for Q1 2026, down 93% quarter-over-quarter.
- 6 funds opened new Iterum Therapeutics positions in Q1 2026 and 8 closed out, a net change of -2 holders.
- The largest Iterum Therapeutics buyer in Q1 2026 was HRT Financial, an estimated $223K added.
- The largest Iterum Therapeutics seller in Q1 2026 was Apollon Financial, an estimated $211K sold.
Based on aggregated 13F filings for Q1 2026.